Literature DB >> 15048093

Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels.

Gersende Alphonse1, Clara Bionda, Marie-Thérèse Aloy, Dominique Ardail, Robert Rousson, Claire Rodriguez-Lafrasse.   

Abstract

Recent strategies to sensitize radioresistant tumours are based on combining gamma-irradiation with inducers of apoptosis. We report that the combination of three inhibitors of sphingolipid metabolism, DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol.HCl(DL-PDMP)+imipramine +/- D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-MAPP), with 10-Gy irradiation triggers both mitotic and apoptotic killing in radioresistant SQ20B squamous carcinoma cells. In these cells, apoptosis is defective due to a lack of ceramide generation upstream, which cannot be explained by sphingomyelinase (neutral and acidic) deficiency or rapid derivation to the sphingolipid pathway. We present evidence of a functional transduction death pathway when ceramide generation is restored, which involves the mitochondrial-mediated pathway coupled to alterations in redox status and to executive caspases activation. The poly-drug treatment restored apoptosis to levels similar to those observed in radiosensitive SCC61 squamous carcinoma cells. Simultaneous exposure to gamma-irradiation and poly-drug treatment acted synergistically in SQ20B cells to produce a marked increase in both mitochondrial dysfunction and caspase cleavage, which led to a 7.8-fold increase in apoptosis within 48 h, relative to irradiated cells. Moreover, the results suggest that the ceramide released by irradiation or poly-drug treatment converges upon common cellular targets. Modulation of endogenous ceramide levels by inhibitors of sphingolipid metabolism may represent a new cellular target for the sensitization of radioresistant tumours to gamma-ray therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048093     DOI: 10.1038/sj.onc.1207357

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis.

Authors:  Leah J Siskind; Thomas D Mullen; Kimberly Romero Rosales; Christopher J Clarke; María José Hernandez-Corbacho; Aimee L Edinger; Lina M Obeid
Journal:  J Biol Chem       Date:  2010-02-18       Impact factor: 5.157

Review 2.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

3.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

Review 4.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis.

Authors:  Jerry E Chipuk; Gavin P McStay; Archana Bharti; Tomomi Kuwana; Christopher J Clarke; Leah J Siskind; Lina M Obeid; Douglas R Green
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

Review 6.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

7.  Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.

Authors:  Yixing Jiang; Nicole A DiVittore; James M Kaiser; Sriram S Shanmugavelandy; Jennifer L Fritz; Yasser Heakal; Hephzibah Rani S Tagaram; Hua Cheng; Myles C Cabot; Kevin F Staveley-O'Carroll; Melissa A Tran; Todd E Fox; Brian M Barth; Mark Kester
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

8.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy.

Authors:  Xiang Liu; Joseph C Cheng; Lorianne S Turner; Saeed Elojeimy; Thomas H Beckham; Alicja Bielawska; Thomas E Keane; Yusuf A Hannun; James S Norris
Journal:  Expert Opin Ther Targets       Date:  2009-12       Impact factor: 6.902

10.  Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.

Authors:  Ayman E M Mahdy; Joseph C Cheng; Jun Li; Saeed Elojeimy; William D Meacham; Lorianne S Turner; Aiping Bai; Christopher R Gault; Alex S McPherson; Nicole Garcia; Thomas H Beckham; Antonio Saad; Alicja Bielawska; Jacek Bielawski; Yusuf A Hannun; Thomas E Keane; Mohhammed I Taha; Hisham M Hammouda; James S Norris; Xiang Liu
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.